Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Researchers from University of Pennsylvania, Medical Department provide details of new studies and findings in the area of cancer vaccines
February 24th, 2009
According to recent research from the United States, "Our laboratory is interested in how immunogenicity may be modulated in vivo in order to better design more effective immunotherapeutics against cancer. Our main approach is to use a facultative intracellular bacterium, Listeria monocytogenes, which has the unusual ability to live and grow in the cytoplasm of the cell and is thus an excellent vector for targeting passenger antigens to the major histocompatibility complex (MHC) class I pathway of antigen processing with the generation of authentic CTL epitopes." "We have used this approach to target tumor antigens expressed on breast, melanoma and cervical cancer. We...
Source: Cancer Weekly (2009-02-24)
|
